Hub : Traits :

Reaction Time

281 significantly associated models · 80 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 48301764 51180660 1 1 1.2e-07 2.7e-08 0.06670 89 AGBL4
2 1 96492298 97978299 1 1 1.0e-09 3.0e-08 0.30000 96 PTBP2
3 1 173437024 175663031 1 1 1.0e-07 1.1e-05 0.12200 88 RABGAP1L
4 1 204991770 206329620 3 1 2.6e-08 2.0e-07 0.39700 97 PM20D1
5 2 23453834 25278723 5 1 9.4e-09 4.7e-08 0.00577 74 AC009228.1
6 2 43844833 45285952 1 1 2.4e-08 7.6e-07 0.07180 87 PREPL
7 2 55483020 57309754 1 1 6.5e-09 2.5e-09 0.01430 83 CCDC85A
8 2 70804467 72356449 1 1 1.3e-07 4.2e-08 1.00000 100 ZNF638
9 2 172619770 173193070 1 1 3.2e-08 4.8e-08 0.34600 97 MAP1D
10 2 174136944 176043097 4 1 6.7e-10 5.7e-10 0.03480 88 OLA1
11 2 200086752 202078494 3 1 1.0e-10 4.0e-12 0.00361 82 SPATS2L
12 3 46365783 47846566 1 1 2.4e-07 2.3e-07 0.04610 85 SETD2
13 5 111499732 112950045 6 1 2.7e-11 3.0e-11 0.30500 98 APC
14 5 138933151 140423473 2 1 9.2e-09 2.5e-09 0.09010 92 PFDN1
15 6 97341715 97979053 1 1 1.2e-08 2.6e-07 0.00022 49 C6orf167
16 6 108183628 109704062 1 1 9.9e-09 7.7e-12 0.00018 70 FOXO3
17 7 32669532 33220866 2 1 2.1e-07 2.2e-07 0.17900 93 KBTBD2
18 7 122978928 124733550 1 1 1.8e-08 3.1e-08 0.00142 67 RP5-921G16.1
19 9 85899677 87315117 1 1 7.7e-09 4.7e-08 0.75800 100 RMI1
20 10 12239118 13839729 1 1 1.4e-09 1.3e-06 0.01840 76 CCDC3
21 11 45945837 47953477 10 1 4.5e-11 2.1e-09 0.07460 91 ARHGAP1
22 11 63295034 64687797 4 1 7.3e-08 1.7e-07 0.51200 98 TRPT1
23 12 48605088 50199949 5 1 5.4e-11 2.4e-12 0.00457 84 CCDC65
24 12 111154626 113517494 12 1 1.9e-11 1.4e-11 0.00886 85 SH2B3
25 16 55526487 57089130 1 1 7.6e-08 2.2e-08 0.11500 92 GNAO1
26 17 43871147 45510971 8 1 5.1e-24 9.1e-20 0.80300 100 ARL17A
27 20 46840115 48410403 2 1 8.4e-08 1.4e-06 0.32700 96 ARFGEF2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 2.14 2 0 0.0 0.00 1.0e+00 RABGAP1L SPATS2L
Bipolar Disorder or Schizophrenia 2.18 3 0 0.0 0.00 1.0e+00 ARHGAP1 OLA1 SPATS2L
Depressed Affect (Nagel 2018) 2.70 5 0 0.0 -0.70 1.9e-01 AC009228.1 ARHGAP1 CCDC85A RABGAP1L SH2B3
Depression (Nagel 2018) 2.70 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Intelligence (Savage-Jansen 2018) 4.77 9 6 13.3 -0.03 9.4e-01 ARFGEF2 ARHGAP1 ARL17A CCDC65 FOXO3 PFDN1 RABGAP1L RMI1 ZNF638
Neuroticism (Nagel 2018) 2.56 4 1 2.2 -0.15 8.5e-01 ARHGAP1 ARL17A CCDC85A RABGAP1L
Schizophrenia (2018) 2.12 1 0 0.0 0.00 1.0e+00 ARHGAP1
Schizophrenia vs Biploar Disorder 2.87 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Worry (Nagel 2018) 2.96 5 0 0.0 0.60 2.8e-01 AGBL4 ARL17A CCDC85A FOXO3 RABGAP1L
Verbal and Numeric Reasoning (VNR) 4.58 7 3 6.7 0.13 7.8e-01 ARFGEF2 ARHGAP1 CCDC65 FOXO3 PFDN1 RABGAP1L ZNF638
Prostate Cancer 1.52 1 0 0.0 0.00 1.0e+00 PM20D1
Coronary Artery Disease (CAD) 1.43 1 0 0.0 0.00 1.0e+00 SH2B3
LDL Cholesterol 1.96 1 0 0.0 0.00 1.0e+00 SH2B3
Primary Biliary Cirrhosis 1.87 1 1 2.2 0.00 1.0e+00 SH2B3
Rheumatoid Arthritis 1.32 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia (2014) 2.00 2 0 0.0 0.00 1.0e+00 ARHGAP1 PTBP2
Blood Eosinophil Count 7.13 2 2 4.4 0.00 1.0e+00 RMI1 SH2B3
Blood Platelet Count 1.82 4 4 8.9 0.11 8.9e-01 ARL17A RMI1 SH2B3 TRPT1
Blood Red Count 1.64 4 2 4.4 0.22 7.8e-01 AC009228.1 ARFGEF2 SH2B3 SPATS2L
Blood White Count 5.02 7 4 8.9 0.13 7.7e-01 AC009228.1 AGBL4 C6orf167 RMI1 SETD2 SH2B3 ZNF638
Heel T-Score 2.04 8 4 8.9 0.10 8.1e-01 APC ARHGAP1 ARL17A CCDC65 RABGAP1L RMI1 SETD2 ZNF638
BMI 2.68 10 6 13.3 -0.28 4.3e-01 AGBL4 ARFGEF2 C6orf167 FOXO3 MAP1D OLA1 PFDN1 PM20D1 PTBP2 TRPT1
Height 2.49 13 10 22.2 0.14 6.4e-01 AC009228.1 APC ARFGEF2 ARL17A CCDC3 CCDC85A FOXO3 PM20D1 RABGAP1L RMI1 RP5-921G16.1 SH2B3 ZNF638
Waist Hip Ratio (WHR) 1.16 2 1 2.2 0.00 1.0e+00 ARL17A SETD2
Systolic Blood Pressure 3.63 7 3 6.7 0.34 4.6e-01 ARFGEF2 ARL17A FOXO3 OLA1 SH2B3 SPATS2L ZNF638
Smoking Status 2.29 3 1 2.2 0.00 1.0e+00 AGBL4 OLA1 RABGAP1L
Allergy or Eczema 1.29 1 0 0.0 0.00 1.0e+00 SH2B3
Cardiovascular Disease 2.72 4 2 4.4 0.61 3.9e-01 ARL17A C6orf167 OLA1 SH2B3
Hypothyroidism (self reported) 4.99 1 1 2.2 0.00 1.0e+00 SH2B3
Type 2 Diabetes (T2D) (2018) 1.37 1 0 0.0 0.00 1.0e+00 SH2B3
Lung FEV1/FVC ratio 1.38 3 2 4.4 0.00 1.0e+00 ARFGEF2 FOXO3 PM20D1
Lung FVC 1.63 6 2 4.4 -0.20 7.0e-01 ARFGEF2 ARL17A FOXO3 RMI1 SH2B3 SPATS2L
Neuroticism 2.82 7 0 0.0 -0.04 9.3e-01 AC009228.1 ARHGAP1 ARL17A CCDC85A MAP1D PFDN1 RABGAP1L
Chronotype (morning person) 2.10 1 1 2.2 0.00 1.0e+00 RMI1
Hair Pigment 0.23 4 3 6.7 -0.72 2.8e-01 CCDC65 FOXO3 PM20D1 SH2B3
Tanning 0.26 2 0 0.0 0.00 1.0e+00 PFDN1 SH2B3
Hand grip strength (left) 2.29 2 1 2.2 0.00 1.0e+00 PM20D1 ZNF638
Number of treatments/medications taken 2.20 2 1 2.2 0.00 1.0e+00 RABGAP1L SH2B3
Sensitivity / hurt feelings 1.52 2 0 0.0 0.00 1.0e+00 ARL17A RMI1
Frequency of depressed mood in last 2 weeks 3.07 3 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1 CCDC85A
Relative age of first facial hair 1.45 1 0 0.0 0.00 1.0e+00 FOXO3
Systolic blood pressure, automated reading 2.73 3 2 4.4 0.00 1.0e+00 ARL17A OLA1 SH2B3
Eye problems/disorders: Diabetes related eye disease 2.22 1 0 0.0 0.00 1.0e+00 KBTBD2
Angina 1.43 1 0 0.0 0.00 1.0e+00 KBTBD2
Vitamin and mineral supplements 1.79 1 0 0.0 0.00 1.0e+00 SETD2
Pack years adult smoking proportion 1.46 1 0 0.0 0.00 1.0e+00 AGBL4
Impedance of leg (right) 1.55 7 1 2.2 0.19 6.8e-01 AC009228.1 CCDC65 FOXO3 GNAO1 PFDN1 PM20D1 SPATS2L
Leg fat-free mass (left) 2.62 10 5 11.1 -0.56 9.0e-02 AGBL4 APC FOXO3 GNAO1 MAP1D OLA1 PM20D1 PTBP2 SH2B3 ZNF638
Trunk fat percentage 2.38 9 2 4.4 -0.25 5.1e-01 AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 RMI1 TRPT1
Hand grip strength (right) 2.30 4 1 2.2 0.31 6.9e-01 ARFGEF2 MAP1D PM20D1 ZNF638
Townsend deprivation index at recruitment 1.15 1 0 0.0 0.00 1.0e+00 AGBL4
Current tobacco smoking 1.68 2 0 0.0 0.00 1.0e+00 AGBL4 CCDC65
Fed-up feelings 2.83 3 1 2.2 0.00 1.0e+00 AC009228.1 ARHGAP1 SH2B3
Relative age voice broke 1.22 1 0 0.0 0.00 1.0e+00 FOXO3
Taking other prescription medications 2.42 2 1 2.2 0.00 1.0e+00 RABGAP1L SH2B3
Age when periods started (menarche) 2.17 2 2 4.4 0.00 1.0e+00 CCDC65 FOXO3
Heel bone mineral density (BMD) T-score, automated (left) 1.45 1 1 2.2 0.00 1.0e+00 ARHGAP1
High blood pressure 2.52 3 1 2.2 0.00 1.0e+00 ARL17A OLA1 SH2B3
Medication: Atenolol 1.99 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Levothyroxine sodium 4.37 1 1 2.2 0.00 1.0e+00 SH2B3
Sitting height 2.78 8 6 13.3 0.37 3.7e-01 AC009228.1 APC ARFGEF2 ARL17A CCDC3 FOXO3 PM20D1 ZNF638
Body mass index (BMI) 2.37 8 3 6.7 -0.08 8.6e-01 AGBL4 C6orf167 FOXO3 MAP1D OLA1 PFDN1 PTBP2 TRPT1
Impedance of leg (left) 1.62 5 1 2.2 0.22 7.2e-01 AC009228.1 GNAO1 PFDN1 PM20D1 SPATS2L
Leg predicted mass (left) 2.61 10 5 11.1 -0.56 8.9e-02 AGBL4 APC FOXO3 GNAO1 MAP1D OLA1 PM20D1 PTBP2 SH2B3 ZNF638
Trunk fat mass 2.64 9 4 8.9 -0.27 4.8e-01 AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 RMI1 TRPT1
Waist circumference 2.25 5 2 4.4 -0.04 9.5e-01 AGBL4 C6orf167 FOXO3 MAP1D OLA1
Past tobacco smoking 2.75 3 0 0.0 0.00 1.0e+00 OLA1 RABGAP1L SH2B3
Alcohol usually taken with meals 2.04 2 0 0.0 0.00 1.0e+00 RABGAP1L RMI1
Nervous feelings 2.40 3 0 0.0 0.00 1.0e+00 AGBL4 ARL17A CCDC85A
Frequency of tenseness / restlessness in last 2 weeks 2.41 2 0 0.0 0.00 1.0e+00 ARL17A RABGAP1L
Hearing difficulty/problems with background noise 2.47 2 0 0.0 0.00 1.0e+00 ARHGAP1 PM20D1
Forced vital capacity (FVC) 1.91 4 2 4.4 -0.29 7.1e-01 ARFGEF2 ARL17A SPATS2L ZNF638
Heel bone mineral density (BMD) T-score, automated (right) 1.28 1 1 2.2 0.00 1.0e+00 ARHGAP1
Qualifications: None of the above 2.84 4 0 0.0 0.57 4.3e-01 ARFGEF2 C6orf167 FOXO3 SPATS2L
Heart attack 1.60 1 0 0.0 0.00 1.0e+00 SH2B3
Fluid intelligence score 3.38 6 2 4.4 -0.10 8.5e-01 ARFGEF2 ARHGAP1 CCDC65 FOXO3 PFDN1 ZNF638
Illnesses of siblings 2.03 1 0 0.0 0.00 1.0e+00 SH2B3
Neuroticism score 2.40 4 0 0.0 -0.24 7.6e-01 ARHGAP1 ARL17A CCDC85A RABGAP1L
Weight 2.81 11 5 11.1 -0.49 1.3e-01 AGBL4 APC ARL17A FOXO3 MAP1D OLA1 PM20D1 PTBP2 SH2B3 TRPT1 ZNF638
Impedance of arm (right) 2.34 6 3 6.7 0.06 9.1e-01 ARL17A FOXO3 PFDN1 PM20D1 RMI1 SH2B3
Arm fat percentage (right) 2.34 9 2 4.4 -0.39 3.0e-01 AGBL4 ARFGEF2 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Trunk fat-free mass 2.70 9 5 11.1 -0.06 8.9e-01 AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 SH2B3 ZNF638
Hip circumference 2.22 7 3 6.7 -0.58 1.8e-01 AGBL4 FOXO3 MAP1D OLA1 PTBP2 SH2B3 TRPT1
Time employed in main current job 1.80 1 0 0.0 0.00 1.0e+00 OLA1
Father's age at death 1.61 1 1 2.2 0.00 1.0e+00 SH2B3
Frequency of tiredness / lethargy in last 2 weeks 2.41 2 0 0.0 0.00 1.0e+00 ARFGEF2 ARHGAP1
Number of live births 1.08 1 0 0.0 0.00 1.0e+00 TRPT1
Forced expiratory volume in 1-second (FEV1) 1.81 2 2 4.4 0.00 1.0e+00 ARFGEF2 ARL17A
Happiness 1.43 1 0 0.0 0.00 1.0e+00 ARFGEF2
Qualifications: A levels/AS levels or equivalent 2.66 3 0 0.0 0.00 1.0e+00 ARFGEF2 C6orf167 SPATS2L
Prospective memory result 2.07 1 0 0.0 0.00 1.0e+00 ZNF638
Forced expiratory volume in 1-second (FEV1), Best measure 1.43 2 2 4.4 0.00 1.0e+00 ARFGEF2 ARL17A
Impedance of arm (left) 2.39 8 3 6.7 0.19 6.5e-01 AGBL4 ARL17A FOXO3 OLA1 PFDN1 RMI1 SH2B3 SPATS2L
Arm fat mass (right) 2.62 8 4 8.9 -0.34 4.1e-01 AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Trunk predicted mass 2.71 9 5 11.1 -0.07 8.7e-01 AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 SH2B3 ZNF638
Standing height 2.47 10 9 20.0 0.14 7.0e-01 AC009228.1 APC ARFGEF2 ARL17A CCDC3 FOXO3 PM20D1 RMI1 SH2B3 ZNF638
Tense / 'highly strung' 2.20 2 1 2.2 0.00 1.0e+00 PM20D1 RABGAP1L
Hair/balding pattern: Pattern 4 1.48 1 0 0.0 0.00 1.0e+00 ARL17A
Birth weight of first child 2.57 2 1 2.2 0.00 1.0e+00 ARFGEF2 SH2B3
Peak expiratory flow (PEF) 2.58 3 1 2.2 0.00 1.0e+00 ARL17A FOXO3 PM20D1
Pulse wave reflection index 1.87 1 0 0.0 0.00 1.0e+00 RMI1
Qualifications: O levels/GCSEs or equivalent 2.96 2 0 0.0 0.00 1.0e+00 ARFGEF2 C6orf167
Medication: Paracetamol 1.61 1 0 0.0 0.00 1.0e+00 RABGAP1L
Headache pain in last month 1.74 1 0 0.0 0.00 1.0e+00 RABGAP1L
Medication for cholesterol, blood pressure or diabetes 1.53 1 1 2.2 0.00 1.0e+00 SH2B3
Gout (self-reported) 1.44 1 0 0.0 0.00 1.0e+00 SH2B3
Hypothyroidism/myxoedema (self-reported) 4.27 1 1 2.2 0.00 1.0e+00 SH2B3
Birth weight 1.86 1 1 2.2 0.00 1.0e+00 SH2B3
High blood pressure (siblings) 1.78 1 0 0.0 0.00 1.0e+00 SH2B3
Forced vital capacity (FVC), Best measure 1.78 3 3 6.7 0.00 1.0e+00 ARFGEF2 ARL17A ZNF638
Body fat percentage 2.38 9 1 2.2 -0.40 2.9e-01 AGBL4 ARFGEF2 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Leg fat percentage (right) 2.26 8 1 2.2 -0.27 5.1e-01 AGBL4 ARFGEF2 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm fat-free mass (right) 2.75 8 6 13.3 -0.59 1.3e-01 AGBL4 APC FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Comparative body size at age 10 2.18 4 2 4.4 0.08 9.2e-01 ARL17A CCDC65 MAP1D PM20D1
Worry too long after embarrassment 1.98 1 1 2.2 0.00 1.0e+00 PFDN1
Seen a psychiatrist for nerves, anxiety, tension or depression 2.13 1 0 0.0 0.00 1.0e+00 PM20D1
Qualifications: College or University degree 2.72 7 2 4.4 -0.23 6.2e-01 ARFGEF2 C6orf167 FOXO3 MAP1D PFDN1 RABGAP1L SPATS2L
Medication for pain relief, constipation, heartburn 1.94 1 1 2.2 0.00 1.0e+00 RABGAP1L
Medication: Blood pressure 2.04 1 1 2.2 0.00 1.0e+00 SH2B3
Angina (self-reported) 1.27 1 0 0.0 0.00 1.0e+00 KBTBD2
Medication: Allopurinol 1.44 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Seretide 50 evohaler 1.60 1 0 0.0 0.00 1.0e+00 AC009228.1
Mean time to correctly identify matches 17.62 27 17 37.8 0.99 2.2e-25 AC009228.1 AGBL4 APC ARFGEF2 ARHGAP1 ARL17A C6orf167 CCDC3 CCDC65 CCDC85A FOXO3 GNAO1 KBTBD2 MAP1D OLA1 PFDN1 PM20D1 PREPL PTBP2 RABGAP1L RMI1 RP5-921G16.1 SETD2 SH2B3 SPATS2L TRPT1 ZNF638
Whole body fat mass 2.65 8 3 6.7 -0.34 4.0e-01 AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Leg fat mass (right) 2.69 7 4 8.9 -0.18 7.0e-01 AGBL4 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm predicted mass (right) 2.77 9 6 13.3 -0.34 3.7e-01 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Pulse rate, automated reading 2.37 5 1 2.2 -0.97 5.9e-03 CCDC65 PM20D1 RABGAP1L SPATS2L TRPT1
Alcohol intake frequency. 1.10 1 0 0.0 0.00 1.0e+00 AC009228.1
Comparative height size at age 10 2.67 9 6 13.3 0.03 9.5e-01 APC ARFGEF2 ARL17A CCDC3 FOXO3 PM20D1 RMI1 SH2B3 ZNF638
Suffer from 'nerves' 2.71 1 0 0.0 0.00 1.0e+00 ARHGAP1
Overall health rating 1.37 2 0 0.0 0.00 1.0e+00 KBTBD2 SPATS2L
Chest pain or discomfort 1.51 1 0 0.0 0.00 1.0e+00 APC
Family relationship satisfaction 1.29 1 0 0.0 0.00 1.0e+00 ARFGEF2
Medication: Aspirin 1.34 1 0 0.0 0.00 1.0e+00 SH2B3
Supplements: Vitamin C 1.59 1 0 0.0 0.00 1.0e+00 RMI1
Knee pain experienced in last month 1.54 1 0 0.0 0.00 1.0e+00 RABGAP1L
Hypertension (Self-reported) 2.35 3 1 2.2 0.00 1.0e+00 ARL17A OLA1 SH2B3
Illnesses of father: Heart disease 1.60 1 0 0.0 0.00 1.0e+00 SH2B3
Smoking status: Previous 2.91 3 0 0.0 0.00 1.0e+00 PREPL RABGAP1L SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 1.65 1 0 0.0 0.00 1.0e+00 ZNF638
Whole body fat-free mass 2.73 10 5 11.1 -0.16 6.6e-01 AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Leg fat-free mass (right) 2.56 9 5 11.1 -0.41 2.7e-01 AC009228.1 AGBL4 FOXO3 GNAO1 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Arm fat percentage (left) 2.18 9 1 2.2 -0.38 3.1e-01 AGBL4 ARFGEF2 ARL17A C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Handedness (chirality/laterality): Left-handed 1.91 1 1 2.2 0.00 1.0e+00 ARL17A
Loneliness, isolation 2.72 3 1 2.2 0.00 1.0e+00 ARFGEF2 ARHGAP1 SH2B3
Mouth/teeth dental problems: Mouth ulcers 1.08 1 0 0.0 0.00 1.0e+00 SH2B3
Medication for cholesterol 1.82 1 1 2.2 0.00 1.0e+00 SH2B3
Illnesses of father: None of the above (group 1) 2.06 2 0 0.0 0.00 1.0e+00 PM20D1 SH2B3
Smoking status: Current 1.72 2 0 0.0 0.00 1.0e+00 AGBL4 CCDC65
Whole body water mass 2.71 10 5 11.1 -0.16 6.6e-01 AC009228.1 AGBL4 APC ARFGEF2 FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Leg predicted mass (right) 2.55 9 5 11.1 -0.41 2.8e-01 AC009228.1 AGBL4 FOXO3 GNAO1 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Arm fat mass (left) 2.60 9 4 8.9 -0.37 3.2e-01 AGBL4 ARL17A C6orf167 FOXO3 MAP1D OLA1 PM20D1 PTBP2 TRPT1
Number of self-reported non-cancer illnesses 2.48 2 1 2.2 0.00 1.0e+00 OLA1 SH2B3
Miserableness 2.62 2 0 0.0 0.00 1.0e+00 AC009228.1 RABGAP1L
Guilty feelings 2.01 2 0 0.0 0.00 1.0e+00 AC009228.1 PFDN1
Medication: Blood pressure 2.11 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Bendroflumethiazide 1.98 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Paracetamol 1.57 1 0 0.0 0.00 1.0e+00 RABGAP1L
Medication: Lisinopril 1.69 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of father: High blood pressure 1.79 1 0 0.0 0.00 1.0e+00 SH2B3
Ever smoked 2.03 1 0 0.0 0.00 1.0e+00 SH2B3
Basal metabolic rate 2.82 9 6 13.3 -0.55 1.3e-01 AGBL4 APC FOXO3 MAP1D OLA1 PM20D1 PTBP2 SH2B3 ZNF638
Leg fat percentage (left) 2.09 8 1 2.2 -0.30 4.8e-01 AGBL4 ARFGEF2 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm fat-free mass (left) 2.90 8 6 13.3 -0.58 1.3e-01 AGBL4 APC FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638
Diastolic blood pressure, automated reading 3.67 5 1 2.2 0.59 2.9e-01 C6orf167 GNAO1 MAP1D OLA1 SH2B3
Ever depressed for a whole week 1.35 1 0 0.0 0.00 1.0e+00 ARFGEF2
Vascular/heart problems diagnosed by doctor 2.63 3 1 2.2 0.00 1.0e+00 OLA1 SH2B3 SPATS2L
Pain experienced in last month 1.92 2 0 0.0 0.00 1.0e+00 RABGAP1L SH2B3
Heart attack/myocardial infarction (self-reported) 1.66 1 0 0.0 0.00 1.0e+00 SH2B3
Pack years of smoking 1.41 1 0 0.0 0.00 1.0e+00 AGBL4
Impedance of whole body 2.10 8 4 8.9 0.15 7.3e-01 ARL17A FOXO3 GNAO1 OLA1 PFDN1 PM20D1 RMI1 SPATS2L
Leg fat mass (left) 2.64 7 3 6.7 -0.19 6.9e-01 AGBL4 C6orf167 FOXO3 MAP1D OLA1 PTBP2 TRPT1
Arm predicted mass (left) 2.83 8 6 13.3 -0.58 1.3e-01 AGBL4 APC FOXO3 MAP1D PM20D1 PTBP2 SH2B3 ZNF638

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 7 0.200 1.9
GTEx Adipose Visceral Omentum 4 0.196 2.0
GTEx Adrenal Gland 5 0.343 2.1
GTEx Artery Aorta 8 0.268 2.0
GTEx Artery Coronary 2 0.169 2.0
GTEx Artery Tibial 8 0.213 2.0
GTEx Brain Caudate basal ganglia 1 0.108 1.9
GTEx Brain Cerebellar Hemisphere 2 0.134 2.0
GTEx Brain Cerebellum 3 0.151 2.0
GTEx Brain Cortex 3 0.290 2.0
GTEx Brain Frontal Cortex BA9 3 0.324 2.1
GTEx Brain Hippocampus 1 0.190 2.0
GTEx Brain Hypothalamus 1 0.169 1.9
GTEx Brain Nucleus accumbens basal ganglia 4 0.462 2.1
GTEx Brain Putamen basal ganglia 1 0.160 2.0
GTEx Breast Mammary Tissue 4 0.202 2.0
GTEx Breast Mammary Tissue (Male) 2 0.168 1.9
GTEx Breast Mammary Tissue (Female) 3 0.182 2.0
GTEx Cells EBV-transformed lymphocytes 2 0.141 1.9
GTEx Cells Transformed fibroblasts 7 0.167 1.9
GTEx Colon Sigmoid 3 0.205 2.0
GTEx Colon Transverse 7 0.339 2.1
GTEx Esophagus Gastroesophageal Junction 6 0.415 2.1
GTEx Esophagus Mucosa 7 0.211 2.0
GTEx Esophagus Muscularis 9 0.278 2.1
GTEx Heart Atrial Appendage 2 0.127 2.0
GTEx Heart Left Ventricle 2 0.130 2.1
GTEx Liver 5 0.696 2.3
GTEx Lung 5 0.174 2.0
GTEx Muscle Skeletal 8 0.277 2.1
GTEx Nerve Tibial 8 0.185 2.0
GTEx Ovary 3 0.330 2.0
GTEx Pancreas 3 0.184 2.0
GTEx Pituitary 7 0.627 2.2
GTEx Prostate 2 0.240 2.0
GTEx Skin Not Sun Exposed Suprapubic 9 0.366 2.0
GTEx Skin Sun Exposed Lower leg 14 0.385 2.0
GTEx Small Intestine Terminal Ileum 1 0.216 1.9
GTEx Spleen 3 0.212 2.0
GTEx Stomach 4 0.275 1.9
GTEx Testis 12 0.380 2.1
GTEx Thyroid 10 0.250 2.0
GTEx Uterus 1 0.176 1.8
GTEx Vagina 0 0.000 1.9
GTEx Whole Blood 1 0.050 2.0
METSIM Adipose 4 0.087 1.9
NTR Blood 1 0.042 1.7
ROSMAP Brain Pre-frontal Cortex 5 0.114 1.9
YFS Blood 6 0.130 1.8
CommonMind Brain Pre-frontal Cortex 9 0.167 1.9
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.8
The Cancer Genome Atlas Breast Invasive Carcinoma 5 0.113 1.8
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 0 0.000 1.7
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 1.8
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.8
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.8
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 2 0.073 1.9
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 6 0.146 1.8
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.097 1.8
The Cancer Genome Atlas Brain Lower Grade Glioma 5 0.116 1.8
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 0 0.000 1.9
The Cancer Genome Atlas Lung Adenocarcinoma 3 0.102 1.8
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 3 0.119 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 2 0.125 1.8
The Cancer Genome Atlas Pancreatic Adenocarcinoma 1 0.060 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 1 0.075 1.8
The Cancer Genome Atlas Prostate Adenocarcinoma 3 0.065 1.8
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.8
The Cancer Genome Atlas Soft Tissue Sarcoma 3 0.280 1.9
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.9
The Cancer Genome Atlas Stomach Adenocarcinoma 3 0.178 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 2 0.156 1.9
The Cancer Genome Atlas Thyroid Carcinoma 6 0.116 1.8
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 2.1